

Ur Metser

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8965309/publications.pdf>

Version: 2024-02-01

78
papers

1,674
citations

257450

24
h-index

330143

37
g-index

80
all docs

80
docs citations

80
times ranked

2607
citing authors

#	ARTICLE	IF	CITATIONS
1	The impact of PSMA PET on the treatment and outcomes of men with biochemical recurrence of prostate cancer: a systematic review and meta-analysis. Prostate Cancer and Prostatic Diseases, 2023, 26, 240-248.	3.9	21
2	Influence of sarcopenia, clinical data, and 2-[18F] FDG PET/CT in outcome prediction of patients with early-stage adenocarcinoma esophageal cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1012-1020.	6.4	9
3	68Ga-PSMA PET in prostate cancer: a systematic review and meta-analysis of the observer agreement. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1021-1029.	6.4	17
4	Effect of ¹⁸ F-DCFPyL PET/CT on the Management of Patients with Recurrent Prostate Cancer: Results of a Prospective Multicenter Registry Trial. Radiology, 2022, 303, 414-422.	7.3	16
5	The clinical consequences of functional adrenal uptake in the absence of cross-sectional mass on FDG-PET/CT in oncology patients. Langenbeck's Archives of Surgery, 2022, 407, 1677-1684.	1.9	1
6	Risk stratification for relapsed/refractory classical Hodgkin lymphoma integrating pretransplant Deauville score and residual metabolic tumor volume. American Journal of Hematology, 2022, 97, 583-591.	4.1	7
7	Combined 18F-FDG PET/CT Radiomics and Sarcopenia Score in Predicting Relapse-Free Survival and Overall Survival in Patients With Esophagogastric Cancer. Clinical Nuclear Medicine, 2022, 47, 684-691.	1.3	14
8	Diagnostic Accuracy of Cardiac MRI versus FDG PET for Cardiac Sarcoidosis: A Systematic Review and Meta-Analysis. Radiology, 2022, 304, 566-579.	7.3	33
9	Impact of ¹⁸ F-DCFPyL PET on Staging and Treatment of Unfavorable Intermediate or High-Risk Prostate Cancer. Radiology, 2022, 304, 600-608.	7.3	10
10	Nasopharyngeal Carcinoma Radiomic Evaluation with Serial PET/CT: Exploring Features Predictive of Survival in Patients with Long-Term Follow-Up. Cancers, 2022, 14, 3105.	3.7	5
11	Ultra-low dose CT abdomen and pelvis for the detection of acute abdominal pathology in the emergency room: initial experience from an academic hospital. Emergency Radiology, 2021, 28, 15-21.	1.8	5
12	How to Design AI-Driven Clinical Trials in Nuclear Medicine. Seminars in Nuclear Medicine, 2021, 51, 112-119.	4.6	17
13	Utilization of Salvage and Systemic Therapies for Recurrent Prostate Cancer as a Result of 18F-DCFPyL PET/CT Restaging. Advances in Radiation Oncology, 2021, 6, 100553.	1.2	7
14	Elective neck dissection versus positron emission tomography-computed tomography-guided management of the neck in clinically node-negative early oral cavity cancer: A cost utility analysis. Cancer, 2021, 127, 1993-2002.	4.1	2
15	Quantitative ⁶⁸ Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with ¹⁷⁷ Lu-DOTATATE. Journal of Nuclear Medicine, 2021, 62, 1406-1414.	5.0	40
16	Salvage lymph node dissection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET)-identified oligometastatic disease. Canadian Urological Association Journal, 2021, 15, E545-E552.	0.6	3
17	Detection of clinically significant prostate cancer with 18F-DCFPyL PET/multiparametric MR. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3702-3711.	6.4	15
18	Deep learning for whole-body medical image generation. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3817-3826.	6.4	12

#	ARTICLE	IF	CITATIONS
19	Management of Wolffian adnexal tumors. International Journal of Gynecological Cancer, 2021, 31, 925-928.	2.5	1
20	Neuroendocrine Tumors. PET Clinics, 2021, 16, 353-364.	3.0	3
21	Establishing a Provincial Registry for Recurrent Prostate Cancer: Providing Access to PSMA PET/CT in Ontario, Canada. Frontiers in Oncology, 2021, 11, 722430.	2.8	5
22	18F-DCFPyL (PSMA) PET in the Management of Men with Biochemical Failure after Primary Therapy: Initial Clinical Experience of an Academic Cancer Center. Current Oncology, 2021, 28, 3251-3258.	2.2	2
23	Predictive radiomics signature for treatment response to nivolumab in patients with advanced renal cell carcinoma. Canadian Urological Association Journal, 2021, 16, .	0.6	2
24	Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. European Urology, 2021, 80, 374-382.	1.9	49
25	Development of a radiomic signature for predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer. Canadian Urological Association Journal, 2021, 16, .	0.6	1
26	The association between lesion tracer uptake on 68Ga-DOTATATE PET with morphological response to 177Lu-DOTATATE therapy in patients with progressive metastatic neuroendocrine tumors. Nuclear Medicine Communications, 2021, Publish Ahead of Print, 73-77.	1.1	3
27	Combined simultaneous FDG-PET/MRI with T1 and T2 mapping as an imaging biomarker for the diagnosis and prognosis of suspected cardiac sarcoidosis. European Journal of Hybrid Imaging, 2021, 5, 24.	1.5	31
28	A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2020, 106, 546-555.	0.8	42
29	Impact of 18F-fluorodeoxyglucose PET/CT in the management of patients with plasma cell disorders. Nuclear Medicine Communications, 2020, 41, 34-39.	1.1	2
30	Convolutional neural networks for improving image quality with noisy PET data. EJNMMI Research, 2020, 10, 105.	2.5	47
31	A risk model for relapsed/refractory aggressive NHL integrating clinical risk factors and pretransplant Deauville score. Blood Advances, 2020, 4, 5762-5771.	5.2	3
32	[¹⁸ F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial. BMJ Open, 2020, 10, e035959.	1.9	8
33	Convolutional Neural Networks in Predicting Nodal and Distant Metastatic Potential of Newly Diagnosed Non-Small Cell Lung Cancer on FDG PET Images. American Journal of Roentgenology, 2020, 215, 192-197.	2.2	37
34	¹⁸ F-DCFPyL PET/CT in Patients with Subclinical Recurrence of Prostate Cancer: Effect of Lesion Size, Smoothing Filter, and Partial-Volume Correction on PROMISE Criteria. Journal of Nuclear Medicine, 2020, 61, 1615-1620.	5.0	4
35	Canadian Urological Association best practice report: Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and PET/magnetic resonance (MR) in prostate cancer. Canadian Urological Association Journal, 2020, 15, 162-172.	0.6	12
36	Primary analysis of a phase II study of metastasis-directed ablative therapy to PSMA (¹⁸ F-DCFPyL) PET-MR/CT defined oligorecurrent prostate cancer.. Journal of Clinical Oncology, 2020, 38, 5553-5553.	1.6	1

#	ARTICLE	IF	CITATIONS
37	CCTG HN.10: A phase II single-arm trial of elective volume adjusted de-escalation radiotherapy (EVADER) in patients with low-risk HPV-related oropharyngeal squamous cell carcinoma (NCT03822897).. Journal of Clinical Oncology, 2020, 38, TPS6592-TPS6592.	1.6	7
38	Case â€“ 18F-DCFPyL-positron emission tomography/computed tomography (PET/CT) time of imaging. Canadian Urological Association Journal, 2020, 15, E376-E379.	0.6	1
39	Preliminary evaluation of 18F-FDG-PET/MRI for differentiation of serous from nonserous pancreatic cystic neoplasms: a pilot study. Nuclear Medicine Communications, 2020, 41, 1257-1264.	1.1	1
40	FDG-PET parameters predict for recurrence in anal cancer â€“ results from a prospective, multicentre clinical trial. Radiation Oncology, 2019, 14, 140.	2.7	22
41	Utility of 18F-FDG-PET/CT imaging in patients with recurrent gynecological malignancies prior to pelvic exenteration. International Journal of Gynecological Cancer, 2019, 29, 816-820.	2.5	0
42	The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of ¹⁸ F-Fluoromethylcholine or ⁶⁸ Ga-HBED-CC PSMA-11 PET/CT in Patients with Biochemical Failure After Radical Prostatectomy. Journal of Nuclear Medicine, 2019, 60, 1253-1258.	5.0	24
43	Repeatability and reproducibility of MRI-based radiomic features in cervical cancer. Radiotherapy and Oncology, 2019, 135, 107-114.	0.6	112
44	Quantitative assessment of dynamic ¹⁸ F-flumethycholine PET and dynamic contrast enhanced MRI in high risk prostate cancer. British Journal of Radiology, 2019, 92, 20180568.	2.2	0
45	Comparison of MRI Sequences in Whole-Body PET/MRI for Staging of Patients With High-Risk Prostate Cancer. American Journal of Roentgenology, 2019, 212, 377-381.	2.2	17
46	Effect of PET/CT on the Management and Outcomes of Participants with Hodgkin and Aggressive Non-Hodgkin Lymphoma: A Multicenter Registry. Radiology, 2019, 290, 488-495.	7.3	22
47	Preliminary results of a two stage phase II study of 18F-DCFPyL PET-MR for enabling oligometastases ablative therapy in subclinical prostate cancer.. Journal of Clinical Oncology, 2019, 37, 250-250.	1.6	0
48	¹⁸ F-FDG PET/CT in the management of patients with malignant pleural mesothelioma being considered for multimodality therapy: experience of a tertiary referral center. British Journal of Radiology, 2018, 91, 20170814.	2.2	10
49	¹⁸ F-Fluorocholine PET Whole-Body MRI in the Staging of High-Risk Prostate Cancer. American Journal of Roentgenology, 2018, 210, 635-640.	2.2	12
50	Measurement of Tumor Hypoxia in Patients With Locally Advanced Cervical Cancer Using Positron Emission Tomography with 18F-Fluoroazomyin Arabinoside. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1202-1209.	0.8	12
51	Applying Radiomics to Predict Pathology of Postchemotherapy Retroperitoneal Nodal Masses in Germ Cell Tumors. JCO Clinical Cancer Informatics, 2018, 2, 1-12.	2.1	21
52	⁶⁸ Ga PET Imaging in Patients With Neuroendocrine Tumors. Clinical Nuclear Medicine, 2018, 43, 802-810.	1.3	50
53	Circulating Human Papillomavirus DNA as a Biomarker of Response in Patients With Locally Advanced Cervical Cancer Treated With Definitive Chemoradiation. JCO Precision Oncology, 2018, 2, 1-8.	3.0	26
54	Effect of Positron Emission Tomography Imaging in Women With Locally Advanced Cervical Cancer. JAMA Network Open, 2018, 1, e182081.	5.9	8

#	ARTICLE	IF	CITATIONS
55	18F-FDG PET/CT metabolic tumor parameters and radiomics features in aggressive non-Hodgkinâ€™s lymphoma as predictors of treatment outcome and survival. <i>Annals of Nuclear Medicine</i> , 2018, 32, 410-416.	2.2	64
56	Benign Cutaneous and Subcutaneous Lesions on FDG-PET/CT. <i>Seminars in Nuclear Medicine</i> , 2017, 47, 352-361.	4.6	17
57	Comparison of 18F-FDG-PET/CT and 18F-FDG-PET/MR imaging in oncology: a systematic review. <i>Annals of Nuclear Medicine</i> , 2017, 31, 366-378.	2.2	38
58	[¹⁸ F]â€FDG PET/CT in the staging and management of indolent lymphoma: A prospective multicenter PET registry study. <i>Cancer</i> , 2017, 123, 2860-2866.	4.1	30
59	Effect of chemotherapy on the impact of FDG-PET/CT in selection of patients for surgical resection of colorectal liver metastases: single center analysis of PET-CAM randomized trial. <i>Annals of Nuclear Medicine</i> , 2017, 31, 153-162.	2.2	2
60	Cystic lesions of the pancreatobiliary tree: A schematic MRI approach. <i>Indian Journal of Radiology and Imaging</i> , 2017, 27, 167-176.	0.8	3
61	FDG-PET/CT in abdominal post-transplant lymphoproliferative disease. <i>British Journal of Radiology</i> , 2016, 89, 20150844.	2.2	18
62	Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients. <i>British Journal of Cancer</i> , 2016, 115, 1186-1192.	6.4	50
63	A prospective study of DWI, DCE-MRI and FDG PET imaging for target delineation in brachytherapy for cervical cancer. <i>Radiotherapy and Oncology</i> , 2016, 120, 519-525.	0.6	41
64	Measurement of Tumor Hypoxia in Patients with Advanced Pancreatic Cancer Based on ¹⁸ F-Fluoroazomyin Arabinoside Uptake. <i>Journal of Nuclear Medicine</i> , 2016, 57, 361-366.	5.0	42
65	Association of Apparent Diffusion Coefficient with Disease Recurrence in Patients with Locally Advanced Cervical Cancer Treated with Radical Chemotherapy and Radiation Therapy. <i>Radiology</i> , 2016, 279, 158-166.	7.3	54
66	FDG PET/CT Response Assessment Criteria for Patients with Hodgkinâ€™s and Non-Hodgkinâ€™s Lymphoma at End of Therapy: A Multiparametric Approach. <i>Nuclear Medicine and Molecular Imaging</i> , 2016, 50, 46-53.	1.0	13
67	Preliminary Results of FDG-PET Scanning after GDP Chemotherapy Prior to Autologous Stem Cell Transplant (ASCT) for Relapsed/Refractory (RR) Lymphoma. <i>Blood</i> , 2016, 128, 4645-4645.	1.4	0
68	Advances in Magnetic Resonance Imaging and Positron Emission Tomography Imaging for Grading and Molecular Characterization of Glioma. <i>Seminars in Radiation Oncology</i> , 2015, 25, 164-171.	2.2	34
69	18F-FDG-PET/CT in assessing response to neoadjuvant chemoradiotherapy for potentially resectable locally advanced esophageal cancer. <i>Annals of Nuclear Medicine</i> , 2014, 28, 295-303.	2.2	20
70	Detection of Urothelial Tumors: Comparison of Urothelial Phase with Excretory Phase CT Urographyâ€”A Prospective Study. <i>Radiology</i> , 2012, 264, 110-118.	7.3	62
71	Evaluation of Upper Urinary Tract Tumors With Portal Venous Phase MDCT: A Case-Control Study. <i>American Journal of Roentgenology</i> , 2011, 197, 424-428.	2.2	14
72	Identification and Quantification of Peritoneal Metastases in Patients With Ovarian Cancer With Multidetector Computed Tomography. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 1391-1398.	2.5	23

#	ARTICLE	IF	CITATIONS
73	Assessment of Tumor Recurrence in Patients With Colorectal Cancer and Elevated Carcinoembryonic Antigen Level: FDG PET/CT Versus Contrast-Enhanced 64-MDCT of the Chest and Abdomen. American Journal of Roentgenology, 2010, 194, 766-771.	2.2	71
74	Assessment of Urinary Tract Calculi With 64-MDCT: The Axial Versus Coronal Plane. American Journal of Roentgenology, 2009, 192, 1509-1513.	2.2	39
75	The Role and Limitations of 18-Fluoro-2-deoxy-d-glucose Positron Emission Tomography (FDG-PET) Scan and Computerized Tomography (CT) in Restaging Patients with Hepatic Colorectal Metastases Following Neoadjuvant Chemotherapy: Comparison with Operative and Pathological Findings. Journal of Gastrointestinal Surgery, 2007, 11, 472-478.	1.7	149
76	Fungal Liver Infection in Immunocompromised Patients: Depiction with Multiphasic Contrast-enhanced Helical CT. Radiology, 2005, 235, 97-105.	7.3	38
77	MR Imaging Findings and Patterns of Spread in Secondary Tumor Involvement of the Uterine Body and Cervix. American Journal of Roentgenology, 2003, 180, 765-769.	2.2	19
78	MRI classification and characterization of complex ovarian masses. , 0, , 6-20.		0